Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer

Ronald S. Walters; Richard L. Theriault; Frankie A. Holmes; Gabriel N. Hortobagyi; Laura Esparza

doi:10.1007/BF01275480

Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer

Ronald S. Walters, Richard L. Theriault, Frankie A. Holmes, Gabriel N. Hortobagyi, Laura Esparza

Breast Medical Oncology

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Fourteen consecutive female patients with metastatic breast cancer received a total of 31 courses of fazarabine at a dose of 2 mg/m²/hour×72 hours (48 mg/m²/day×3) as a continuous infusion. There were no responses seen, although one patient achieved stability of her disease for five courses. Because of encouraging in vitro results and the primarily hematologic dose-limiting toxicity, further study in combination with colony stimulating growth factors might be of interest.

Original language	English (US)
Pages (from-to)	43-44
Number of pages	2
Journal	Investigational New Drugs
Volume	10
Issue number	1
DOIs	https://doi.org/10.1007/BF01275480
State	Published - Mar 1992

Keywords

arabinosyl-5-azacytosine
breast cancer chemotherapy
fazarabine

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF01275480

Cite this

@article{ecb9f214cbe14fb88bd688c9ac89dfc0,

title = "Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer",

abstract = "Fourteen consecutive female patients with metastatic breast cancer received a total of 31 courses of fazarabine at a dose of 2 mg/m2/hour×72 hours (48 mg/m2/day×3) as a continuous infusion. There were no responses seen, although one patient achieved stability of her disease for five courses. Because of encouraging in vitro results and the primarily hematologic dose-limiting toxicity, further study in combination with colony stimulating growth factors might be of interest.",

keywords = "arabinosyl-5-azacytosine, breast cancer chemotherapy, fazarabine",

author = "Walters, {Ronald S.} and Theriault, {Richard L.} and Holmes, {Frankie A.} and Hortobagyi, {Gabriel N.} and Laura Esparza",

year = "1992",

month = mar,

doi = "10.1007/BF01275480",

language = "English (US)",

volume = "10",

pages = "43--44",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "1",

}

TY - JOUR

T1 - Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer

AU - Walters, Ronald S.

AU - Theriault, Richard L.

AU - Holmes, Frankie A.

AU - Hortobagyi, Gabriel N.

AU - Esparza, Laura

PY - 1992/3

Y1 - 1992/3

N2 - Fourteen consecutive female patients with metastatic breast cancer received a total of 31 courses of fazarabine at a dose of 2 mg/m2/hour×72 hours (48 mg/m2/day×3) as a continuous infusion. There were no responses seen, although one patient achieved stability of her disease for five courses. Because of encouraging in vitro results and the primarily hematologic dose-limiting toxicity, further study in combination with colony stimulating growth factors might be of interest.

AB - Fourteen consecutive female patients with metastatic breast cancer received a total of 31 courses of fazarabine at a dose of 2 mg/m2/hour×72 hours (48 mg/m2/day×3) as a continuous infusion. There were no responses seen, although one patient achieved stability of her disease for five courses. Because of encouraging in vitro results and the primarily hematologic dose-limiting toxicity, further study in combination with colony stimulating growth factors might be of interest.

KW - arabinosyl-5-azacytosine

KW - breast cancer chemotherapy

KW - fazarabine

UR - http://www.scopus.com/inward/record.url?scp=0026636656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026636656&partnerID=8YFLogxK

U2 - 10.1007/BF01275480

DO - 10.1007/BF01275480

M3 - Article

C2 - 1376723

AN - SCOPUS:0026636656

SN - 0167-6997

VL - 10

SP - 43

EP - 44

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Phase II trial of fazarabine (ARA-AC, arabinosyl-5-azacytosine) in metastatic breast cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this